Seegene

Seegene Total Assets

The Total Assets of Seegene (096530.KQ) as of Nov 16, 2026 is 1.24 T KRW. In the previous year, Total Assets was 1.21 T KRW — a change of 2.53% (higher).

Total Assets

1.24 TKRW

YoY

2.53%

Last updated:

Total Assets of Seegene is 2025 1.24 T KRW. Total Assets of Seegene was 2024 1.21 T KRW. It decreases by 2.53% higher compared to the previous year.

The Seegene Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
163.81 B KRW
Jan 1, 2019
195.72 B KRW
Jan 1, 2020
1.09 T KRW
Jan 1, 2021
1.49 T KRW
Jan 1, 2022
1.39 T KRW
Jan 1, 2023
1.25 T KRW
Jan 1, 2024
1.21 T KRW
Jan 1, 2025
1.24 T KRW
The Seegene Total Assets history
YEARTotal AssetsYoY
1.24 TKRW+2.53%
1.21 TKRW-3.69%
1.25 TKRW-10.02%
1.39 TKRW-6.64%
1.49 TKRW+36.10%
1.09 TKRW+459.27%
195.72 BKRW+19.48%
163.81 BKRW-0.63%
164.84 BKRW-20.60%
207.62 BKRW+6.99%
194.05 BKRW+40.15%
138.45 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Total Assets of Seegene is 1.24 T KRW in 2025.

Total Assets of Seegene changed from 1.21 T KRW to 1.24 T KRW, representing a 2.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Seegene since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Seegene

All Key Metrics — Seegene